Results 231 to 240 of about 3,024,443 (298)
Interplay of integrins and selectins in metastasis
Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva+2 more
wiley +1 more source
Could his Bundle be Easily Reached and Effectively Paced with Current Lead Systems? The South European Select Secure Registry Experience [PDF]
Francesco Zanon+9 more
openalex +1 more source
Mid-term comparison of new-onset AHRE between His bundle and left bundle branch area pacing in patients with AV block. [PDF]
Pestrea C+8 more
europepmc +1 more source
Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson+11 more
wiley +1 more source
Intra-His Bundle Block Following Ligation of Anterior Septal Artery in Dog
Kazuhiko Murata+4 more
openalex +2 more sources
Longitudinal assessment of tricuspid regurgitation following conduction system pacing. [PDF]
Oida M+11 more
europepmc +1 more source
Microglia act as tumor suppressors during brain metastasis colonization but shift to a tumor‐promoting role after melanoma brain metastases form. NF‐κB/RelA signaling emerges as a key driver of this phenotypic shift. Targeting this pathway reprograms microglia into a pro‐inflammatory state, enhancing antitumor immunity and immune checkpoint inhibitor ...
Noam Savion‐Gaiger+2 more
wiley +1 more source
Editorial to "Mid-term comparison of new-onset AHRE between His bundle and left bundle branch area pacing in patients with AV block". [PDF]
Noda T.
europepmc +1 more source
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu+11 more
wiley +1 more source